Standard BioTools Inc. (LAB) Guidance & Earnings Results

On 2026-08-05 Standard BioTools Inc. issued guidance: "Full year 2026 revenue outlook withdrawn due to pending merger with Treeline…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

LABStandard BioTools Inc.Follow LAB — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 237.7M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 10 Nov, in 17 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	—	Full year 2026 revenue outlook withdrawn due to pending merger with Treeline Biosciences. · full year
5 May 26	Reaffirmed	FY2026 revenue $80-85M · full year
24 Feb 26	—	Full Year 2026 Revenue Outlook provided but not quantified in excerpt; path to positive adjusted EBITDA and cash flow exiting 2026 · full year
4 Nov 25	Reaffirmed	FY2025 combined revenue $165-175M; continuing ops revenue $78-83M · full year
11 Aug 25	Reaffirmed	FY2025 combined revenue $165-175M; continuing ops revenue $78-83M. · full year

Standard BioTools Inc. — questions

What guidance did Standard BioTools Inc. give?: On 2026-08-05: "Full year 2026 revenue outlook withdrawn due to pending merger with Treeline Biosciences."
When does Standard BioTools Inc. report earnings?: Standard BioTools Inc.'s next earnings report is expected on 2026-11-10.

Every figure on this page comes from Standard BioTools Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.